Renal Cancer
The road to improving doctor-patient interactions in kidney cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
Stereotactic radiotherapy with pembrolizumab promising for oligometastatic kidney cancer
Immunotherapy combo fails to improve overall survival in advanced kidney cancer
Belzutifan shows benefit in two conditions that spark tumor growth
TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Best of EAU: Immune cell populations have prognostic value in RCC
KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC
PSMA PET-CT more accurate than standard-of-care imaging in RCC
Worse renal function after radical versus partial nephrectomy
Post-nephrectomy pembrolizumab improves disease-free survival
Glutaminase inhibitor telaglenastat does not improve survival mRCC
Single-cell mRNA signaling facilitates diagnosis of childhood and adult kidney tumors
Post-surgery immunotherapy could be new standard of care in common kidney cancer
CLEAR trial: promising new combination to treat RCC
CheckMate 9ER offers RCC new frontline option
ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC
Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma
Inflammatory markers may guide treatment decisions in metastatic renal cell cancer
Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?
Axitinib offers hope for improving renal cell cancer surgical outcomes
Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma
Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma
Nivolumab-cabozantinib combo boosts survival over sunitinib in kidney cancer
Chronic kidney disease patients need close monitoring during Ramadan fast
Details released for CLEAR study on advanced renal cell carcinoma
ACE2-generated small peptide shows promise in clear-cell kidney cancer
KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib
Debate: upfront cytoreductive nephrectomy or not?
Robotic-assisted partial nephrectomy: lower morbidity
Novel mode of action for kidney cancer treatment
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
